Exelixis (EXEL) Receives a Buy from William Blair

William Blair analyst Andy Hsieh reiterated a Buy rating on Exelixis (EXELResearch Report) on October 9. The company’s shares closed last Friday at $23.23.

According to TipRanks.com, Hsieh is a 5-star analyst with an average return of 23.9% and a 65.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and Beyondspring.

Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $32.17.

See today’s analyst top recommended stocks >>

Based on Exelixis’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $259 million and net profit of $66.82 million. In comparison, last year the company earned revenue of $240 million and had a net profit of $79.04 million.

Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXEL in relation to earlier this year. Last month, Charles Cohen, a Director at EXEL bought 115,396 shares for a total of $671,605.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.